MY139933A - Composition and its therapeutic use - Google Patents

Composition and its therapeutic use

Info

Publication number
MY139933A
MY139933A MYPI20024929A MYPI20024929A MY139933A MY 139933 A MY139933 A MY 139933A MY PI20024929 A MYPI20024929 A MY PI20024929A MY PI20024929 A MYPI20024929 A MY PI20024929A MY 139933 A MY139933 A MY 139933A
Authority
MY
Malaysia
Prior art keywords
cells
composition
therapeutic use
tumour
vitamin
Prior art date
Application number
MYPI20024929A
Other languages
English (en)
Inventor
Mishal Hamid Al-Sari
Original Assignee
Insignion Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insignion Holdings Ltd filed Critical Insignion Holdings Ltd
Publication of MY139933A publication Critical patent/MY139933A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Birds (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
MYPI20024929A 2002-05-29 2002-12-30 Composition and its therapeutic use MY139933A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0212405.5A GB0212405D0 (en) 2002-05-29 2002-05-29 Composition and its therapeutic use

Publications (1)

Publication Number Publication Date
MY139933A true MY139933A (en) 2009-11-30

Family

ID=9937661

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI20024929A MY139933A (en) 2002-05-29 2002-12-30 Composition and its therapeutic use
MYPI20031995A MY134288A (en) 2002-05-29 2003-05-29 Composition and its therapeutic use

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI20031995A MY134288A (en) 2002-05-29 2003-05-29 Composition and its therapeutic use

Country Status (30)

Country Link
EP (2) EP1513546A1 (enExample)
JP (3) JP4362441B2 (enExample)
CN (3) CN1655811A (enExample)
AP (1) AP2004003177A0 (enExample)
AR (1) AR039895A1 (enExample)
AT (1) ATE468134T1 (enExample)
AU (4) AU2003236893A1 (enExample)
BR (1) BR0311371A (enExample)
CA (1) CA2487678A1 (enExample)
DE (1) DE60332578D1 (enExample)
EA (1) EA010548B1 (enExample)
EC (1) ECSP045458A (enExample)
GB (3) GB0212405D0 (enExample)
IL (1) IL164952A0 (enExample)
IS (1) IS7578A (enExample)
MA (1) MA27207A1 (enExample)
ME (1) MEP22908A (enExample)
MX (1) MXPA04011794A (enExample)
MY (2) MY139933A (enExample)
NO (1) NO20044768L (enExample)
NZ (1) NZ536360A (enExample)
OA (1) OA12862A (enExample)
PL (1) PL374199A1 (enExample)
RS (1) RS102304A (enExample)
SM (1) SM200300009A (enExample)
TN (1) TNSN04235A1 (enExample)
TW (1) TW200425892A (enExample)
UY (1) UY27827A1 (enExample)
WO (1) WO2003101479A1 (enExample)
ZA (2) ZA200210316B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
GB0501654D0 (en) * 2005-01-26 2005-03-02 Veritron Ltd Stabilised plant extract
GB0523257D0 (en) * 2005-11-15 2005-12-21 Veritron Ltd Purification process
GB0710536D0 (en) 2007-06-01 2007-07-11 Veritron Ltd Plant extract and its therapeutic use
DE102007030103A1 (de) 2007-06-28 2009-01-02 Bode Chemie Gmbh & Co. Kg Verwendung einer synergistischen Zusammensetzung als therapeutisches oder kosmetisches Mittel
GB0808974D0 (en) * 2008-05-16 2008-06-25 Veritron Ltd Plant extract and its therapeutic use
EP2420228A1 (en) 2010-08-05 2012-02-22 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer
JP5756326B2 (ja) * 2011-04-14 2015-07-29 一丸ファルコス株式会社 キネシン抑制剤
EP2813515B1 (en) * 2012-02-07 2019-07-10 PHI Biomed Co., Ltd. Transdermally delivered hyaluronic acid-protein conjugate
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
FR3057773B1 (fr) * 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
AU2021351504A1 (en) * 2020-09-30 2023-05-25 Reven Pharmaceuticals Inc. Pharmaceutical compositions and methods for prevention and/or treatment of inflammation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98342C (da) * 1959-06-16 1964-03-31 Henry Marinus Dr Christensen Fremgangsmåde til fremstilling af et insulinpræparat til peroral applikation.
FR2126134A1 (en) * 1971-02-26 1972-10-06 Ates Ibrahim Cyclophosphamide/magnesium compsns - with enhanced cytostatic activity
JPH02144075A (ja) * 1988-11-25 1990-06-01 Olympus Optical Co Ltd 薬剤放出装置
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
JP2902886B2 (ja) * 1992-12-28 1999-06-07 三洋電機株式会社 記録ディスク演奏装置
CA2112539A1 (en) * 1993-12-29 1995-06-30 Romualdo D. Candelario Medicated herbal lotion
IT1269826B (it) * 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
JPH08176002A (ja) * 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
PT802257E (pt) * 1996-04-19 2003-01-31 Nestle Sa Linhagem imortalizada de celulas epiteliais do colon humano
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
JP2000086510A (ja) * 1998-09-16 2000-03-28 Oriza Yuka Kk ヒスタミン遊離抑制剤
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
AU6174900A (en) * 1999-07-08 2001-01-30 Patrick T. Prendergast Use of flavones, coumarins and related compounds to treat infections
JP2003508437A (ja) * 1999-08-30 2003-03-04 オキシカル・ラボラトリーズ・インク 選択的癌化学療法及び該療法用の組成物
AU779798C (en) * 1999-11-15 2005-11-17 Hanamaraddi T. Gangal Dextrose and insulin fluid formulation for intravenous infusion
US6291533B1 (en) * 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type
HK1046848B (zh) * 2000-03-03 2006-04-13 李叔文 爱滋病特效药
EP1195159B1 (en) * 2000-10-09 2006-05-31 Rath, Matthias, Dr. med. Therapeutic combination of ascorbate with lysine and arginine for prevention and treatment of cancer
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use

Also Published As

Publication number Publication date
IL164952A0 (en) 2005-12-18
IS7578A (is) 2004-12-01
SM200300009B (it) 2004-12-01
RS102304A (sr) 2006-12-15
CN1466994A (zh) 2004-01-14
PL374199A1 (en) 2005-10-03
GB2392618A (en) 2004-03-10
EA200401586A1 (ru) 2005-04-28
AU2003204391A1 (en) 2003-12-18
EP1366768B1 (en) 2010-05-19
GB2427824A (en) 2007-01-10
GB2392618B (en) 2007-02-21
AU2003204391B2 (en) 2005-08-04
JP4362441B2 (ja) 2009-11-11
AR039895A1 (es) 2005-03-09
DE60332578D1 (de) 2010-07-01
EA010548B1 (ru) 2008-10-30
EP1513546A1 (en) 2005-03-16
BR0311371A (pt) 2005-04-05
AU2007203159B2 (en) 2009-03-26
AU2009200893A1 (en) 2009-04-09
AP2004003177A0 (en) 2004-12-31
MEP22908A (en) 2010-06-10
MA27207A1 (fr) 2005-01-03
AU2003236893A1 (en) 2003-12-19
OA12862A (en) 2006-09-15
TW200425892A (en) 2004-12-01
UY27827A1 (es) 2003-12-31
ZA200210316B (en) 2003-07-04
CN101380463A (zh) 2009-03-11
GB0325839D0 (en) 2003-12-10
CN1655811A (zh) 2005-08-17
CA2487678A1 (en) 2003-12-11
ECSP045458A (es) 2005-05-30
EP1366768A1 (en) 2003-12-03
MY134288A (en) 2007-11-30
ATE468134T1 (de) 2010-06-15
JP2004002429A (ja) 2004-01-08
JP2009143947A (ja) 2009-07-02
NZ536360A (en) 2008-03-28
TNSN04235A1 (en) 2007-03-12
MXPA04011794A (es) 2005-07-05
AU2007203159A1 (en) 2007-07-26
GB0615918D0 (en) 2006-09-20
ZA200409551B (en) 2005-10-11
SM200300009A (it) 2004-12-01
WO2003101479A1 (en) 2003-12-11
NO20044768L (no) 2005-02-24
JP2006500324A (ja) 2006-01-05
GB0212405D0 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
MY139933A (en) Composition and its therapeutic use
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
WO2009148623A3 (en) Methods and related compositions for the treatment of cancer
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
EP4400172A3 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MY158106A (en) Inhibitors of e1 activating enzymes
TW200510328A (en) 5-membered heterocycle-based p38 kinase inhibitors
EP4292650A3 (en) Heterocyclic compounds as immunomodulators
IN2012DN03824A (enExample)
TNSN07076A1 (en) New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
UA89226C2 (en) Imidazole compounds
PH12012501054A1 (en) Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
RU2009138327A (ru) Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
Mantovani et al. Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
ZA202109831B (en) Bioenergetic combinations and methods of using same
NZ580533A (en) Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
MY137563A (en) Ophthalmic composition
MX2007002525A (es) Compuestos de difeniletileno y usos de los mismos.
SI1638582T1 (sl) Uporaba hialuronske kisline za pripravo sestav za zdravljenje ponavljajoäśih se aft v ustni votlini
TW200735863A (en) Dietary compositions for enhancing metabolism and reducing reactive oxygen species
AU2017401761A8 (en) Synergistic composition for maintenance of healthy balance of microflora
PH12022550952A1 (en) Antimicrobial compositions comprising modified clay and copolymers